Market Data 
Markets
Replies to post #222052 on Biotech Values
03/08/19 9:14 AM
Stellar Biotechnologies, Inc. (SBOT), a leading manufacturer of a key protein utilized in immunotherapy and immuno-oncology development pipelines, has executed a share exchange agreement with privately-held Edesa Biotech Inc…to create a company focused on the development of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs.
…Following the closing, current Stellar shareholders are expected to own approximately 10%, and the current shareholders of Edesa are expected to own approximately 90%, of the combined company on a fully-diluted basis…
…Following closing, Stellar intends to develop a plan for the disposition of Stellar's operations, which is expected to include the wind down or spin-off of Stellar's legacy business.
AI
